RecallDepth
Class II Ongoing

fentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.1% Bupivacaine HCl 100 mg/100 mL (1 mg/mL), 100 ml in NS Yellow CADD FSFF, Injection for Epidural Use (Not intended For IV Use), Compounded, For Institutional or Office Use Only, QuVa Pharma, 1075 West Park One Drive, Suite 100, Sugar Land, Tx 77478. NDC: 70092-1255-75

This recall is currently active, issued April 2, 2025. It was issued by Quva Pharma, Inc..

Company
Quva Pharma, Inc.
Recall Initiated
March 6, 2025
Posted
April 2, 2025
Recall Number
D-0295-2025
Voluntary / Mandated
Voluntary: Firm initiated
Firm Location
Sugar Land, TX, United States
Official Source
View on FDA website ↗

Reason for Recall

Lack of Assurance of Sterility

Distribution

U.S. Nationwide

Lot / Code Info

Lots: 10140259, 10140539, 10140687, 10140688; Exp 04/24/2025

More recalls by Quva Pharma, Inc.

View all recalls by this company →

Other recent Class II Drug recalls